# First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer

> **NCT02716012** · PHASE1 · UNKNOWN · sponsor: **Mina Alpha Limited** · enrollment: 75 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Liver Cancer

## Interventions

- **DRUG:** MTL-CEBPA
- **DRUG:** Sorafenib 200mg

## Key facts

- **NCT ID:** NCT02716012
- **Lead sponsor:** Mina Alpha Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03-01
- **Primary completion:** 2025-07-01
- **Final completion:** 2025-07-31
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02716012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02716012, "First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02716012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*